Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digitalis.

P J Hauptman1, R A Kelly

  • 1Department of Medicine, Division of Cardiology, Saint Louis University School of Medicine, St. Louis, MO, USA.

Circulation
|March 9, 1999
PubMed
Summary
This summary is machine-generated.

Cardiac glycosides, like digoxin, remain valuable for managing heart failure symptoms alongside other therapies. However, their use may decrease as newer treatments become available.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting physiologically-relevant oxygen concentrations in precision-cut liver slices using mathematical modelling.

PloS one·2022
Same author

Cytokines and cardiac hypertrophy: roles of angiotensin II and basic fibroblast growth factor.

Clinical and experimental pharmacology & physiology·2010
Same author

Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease.

Gene therapy·2007
Same author

Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study.

The Journal of thoracic and cardiovascular surgery·2003
Same author

In vivo electrophysiologic studies in endothelial nitric oxide synthase (eNOS)-deficient mice.

Journal of cardiovascular electrophysiology·2002
Same author

Nitric oxide and cardiac contractility in human heart failure: time for reappraisal.

Circulation·2001
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiology
  • Toxicology

Background:

  • Cardiac glycosides, derived from Digitalis purpurea, have been used for heart failure since the 18th century.
  • Despite long-term use, their efficacy and safety remain subjects of debate.
  • The precise mechanism of action, whether sympatholytic or positive inotropic, is still discussed.

Purpose of the Study:

  • To review the molecular and clinical pharmacology of cardiac glycosides.
  • To discuss manifestations and treatment of digitalis toxicity.
  • To analyze recent clinical trials on cardiac glycoside efficacy in heart failure.

Main Methods:

  • Literature review of molecular and clinical pharmacology.
  • Analysis of digitalis toxicity and treatment strategies.

Related Experiment Videos

  • Detailed examination of clinical trials, including the Digoxin Investigation Group data.

    • Main Results:

    • Cardiac glycosides are effective for heart failure symptom management when used with contemporary multidrug therapy.
    • The molecular target, Na+K+-ATPase, is well-established but its role in therapeutic effects is debated.
    • Digitalis toxicity and its management are critical considerations.

    Conclusions:

    • Cardiac glycosides offer continued benefit for heart failure symptom relief in patients on comprehensive therapy.
    • The role of cardiac glycosides is expected to diminish with advancements in pharmacotherapy.
    • Ongoing research and clinical trials are essential for understanding their place in modern heart failure treatment.